Leading NHS hospitals have adopted the SAMBA III rapid molecular diagnostics platform to transform the way patients with suspected respiratory infections are assessed and managed.

“Using SAMBA III will give us greater flexibility meaning that our patients are cared for in the right place at the right time”, Head of Infection Prevention and Control, Medway Maritime Hospital.

Rapid respiratory testing is increasingly recognised as an essential component of modern healthcare. By significantly reducing the time taken to identify respiratory pathogens, clinicians can make informed decisions sooner, helping to optimise isolation measures, direct patients to the most appropriate ward, reduce unnecessary bed occupancy, and support infection prevention across the hospital.

The SAMBA III platform builds on the proven success of the SAMBA technology, which has supported more than 100 NHS hospitals by delivering simple, accurate molecular testing where patients need it most. The latest generation platform offers faster turnaround times, expanded multiplex testing capability and seamless connectivity, enabling hospitals to respond efficiently to seasonal respiratory viruses and emerging infectious disease challenges.

Hear more from the team at Medway Maritime Hospital: SAMBA III video at Medway